{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:48:15Z","timestamp":1778687295296,"version":"3.51.4"},"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0006837","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T13:43:57Z","timestamp":1542289437000},"page":"e0006837","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years"],"prefix":"10.1371","volume":"12","author":[{"given":"Piero L.","family":"Olliaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette C.","family":"Kuesel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Halleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-1034","authenticated-orcid":true,"given":"Mark","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Reeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"ref1","unstructured":"World Health Organization (WHO). Accelerating work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. 2012. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/70809\/WHO_HTM_NTD_2012.1_eng.pdf;jsessionid=8115ABBD2F06456FFA3D7EF24984D79B?sequence=1<\/ext-link>. [cited 2018 August 28]."},{"key":"ref2","unstructured":"Policy cures Research. G-Finder 2017. Neglected disease research and development. Reflecting on a decade of global investment. http:\/\/policycuresresearch.org\/downloads\/Y10_G-FINDER_full_report.pdf<\/ext-link>. [cited 2018 August 28]."},{"issue":"9324","key":"ref3","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"P Trouiller","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000\u201311): a systematic assessment","volume":"1","author":"B Pedrique","year":"2013","journal-title":"Lancet Glob Health"},{"key":"ref5","unstructured":"US Department of Health and Human Services. US Food and Drug Administration website. Food and Drug Administration Amendments Act (FDAAA) of 2007. https:\/\/www.fda.gov\/RegulatoryInformation\/LawsEnforcedbyFDA\/SignificantAmendmentstotheFDCAct\/FoodandDrugAdministrationAmendmentsActof2007\/default.htm<\/ext-link>. [cited 2018 August 28]."},{"key":"ref6","unstructured":"Priority Review Voucher. http:\/\/priorityreviewvoucher.org<\/ext-link>. [cited 2018 August 28]."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"g4665","DOI":"10.1136\/bmj.g4665","article-title":"US incentive scheme for neglected diseases: a good idea gone wrong?","volume":"349","author":"Peter Doshi","year":"2014","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"g4665","DOI":"10.1136\/bmj.g4665","article-title":"US incentive scheme for neglected diseases: a good idea gone wrong?\u2013a response from TDR","volume":"349","author":"PL Olliaro","year":"2014","journal-title":"BMJ"},{"key":"ref9","unstructured":"World Health Organization (WHO). Crossing the billion. Lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiases and trachoma: preventive chemotherapy for neglected tropical diseases. 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255498\/1\/9789241512152-eng.pdf?ua=1<\/ext-link>. [cited 2018 August 28]."},{"key":"ref10","unstructured":"World Health Organization (WHO): Onchocerciasis. Status of endemicity of onchocerciasis: 2016. http:\/\/apps.who.int\/neglected_diseases\/ntddata\/oncho\/onchocerciasis.html<\/ext-link>. [cited 2018 August 28]."},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"e0003664","DOI":"10.1371\/journal.pntd.0003664","article-title":"Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa","volume":"9","author":"YE Kim","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpddr.2016.04.002","article-title":"Research for new drugs for elimination of onchocerciasis in Africa","volume":"6","author":"AC Kuesel","year":"2016","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"e2953","DOI":"10.1371\/journal.pntd.0002953","article-title":"A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection","volume":"8","author":"K Awadzi","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref14","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","author":"NO Opoku","year":"2018","journal-title":"Lancet"},{"key":"ref15","unstructured":"US Department of Health and Human Services. US Food and Drug Administration website. FDA-Approved Drug Products database. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=210867<\/ext-link>. [cited 2018 August 28]."},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1377\/hlthaff.2015.1314","article-title":"The Commercial Market For Priority Review Vouchers","volume":"35","author":"DB Ridley","year":"2016","journal-title":"Health Aff (Millwood)"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0006837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T17:42:02Z","timestamp":1588959722000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0006837"}},"subtitle":[],"editor":[{"given":"Rhoel Ramos","family":"Dinglasan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0006837","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]}}}